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Abstract 32 
OBJECTIVES: To evaluate potential anti-biofilm agents for their ability to enhance the 33 
activity of antibiotics for local treatment of localised biofilm infections.  34 
METHODS: Staphylococcus aureus and Pseudomonas aeruginosa in vitro biofilm models 35 
were developed. The putative antibiotic enhancers N-acetylcysteine, acetylsalicylic acid, 36 
sodium salicylate, rhDNase I, Dispersin B, hydrogen peroxide, and Baby Shampoo were 37 
tested for their anti-biofilm activity alone and their ability to enhance the activity of antibiotics 38 
for seven or 14 days, against five-day-old biofilms. The antibiotic enhancers were paired with 39 
rifampicin and clindamycin against S. aureus and gentamicin and ciprofloxacin against P. 40 
aeruginosa. Isolates from biofilms that were not eradicated were tested for antibiotic 41 
resistance.  42 
RESULTS: Antibiotic levels 10xMIC and 100xMIC significantly reduced biofilm but did not 43 
consistently eradicate it. Antibiotics at 100xMIC with 10% Baby Shampoo for 14 days was 44 
the only treatment to eradicate both staphylococcal and pseudomonal biofilms. RhDNase I 45 
significantly reduced staphylococcal biofilm. Emergence of resistance of surviving isolates 46 
was minimal and was often associated with Small Colony Variant phenotype.  47 
CONCLUSIONS: Baby Shampoo enhanced the activity of antibiotics and several other 48 
promising anti-biofilm agents were identified. Antibiotics with 10% Baby Shampoo eradicated 49 
biofilms produced by both organisms. Such a combination might be useful in local treatment 50 
of localised biofilm infections. 51 
 52 
Introduction 53 
Biofilms are an important cause of persistent and chronic infections such as otitis 54 
media with effusion (OME),1,2 prosthetic joint infections,3 colonisation of other indwelling 55 
devices,4 and infections after trauma, either following the injury itself or the surgical 56 
treatment.5 The biofilm mode of growth has many strategies for persistence and in this state, 57 
only essential processes remain active, and therefore many target sites for antibiotics are 58 
down-regulated leading to reduced susceptibility to antibiotics.6,7 Biofilm eradication requires 59 
10-1,000 times the MIC of antibiotics normally needed to inhibit the planktonic form.8,9 Such 60 
high levels of antibiotics would be difficult to achieve safely when administered 61 
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systemically.10 Many biofilm infections are localised, for instance around spinal and 62 
orthopaedic implants, in trauma, or in chronic wounds or facial sinuses. Local administration 63 
of antibiotics in such situations results in very high concentrations at the biofilm site while 64 
avoiding systemic exposure, but even then, failures occur due to incomplete eradication of 65 
the biofilm. 66 
Therefore, there is a need for alternative anti-biofilm strategies that might enable 67 
locally administered antibiotics to exert anti-biofilm effect more consistently while if possible 68 
reducing the concentrations necessary. Agents that disrupt the biofilm matrix may enhance 69 
the anti-biofilm activity of antibiotics so that the biofilm cells become once again susceptible 70 
to antibiotic treatment. We identified the following agents that could potentially be ‘antibiotic 71 
enhancers’: N-acetylcysteine (NAC),11,12 acetylsalicylic acid,13,14 sodium salicylate,15,16 72 
salicylic acid,17,18 recombinant human deoxyribonuclease I (rhDNAse I),19,20 Dispersin B,21 73 
hydrogen peroxide,22 and Johnson’s Baby Shampoo (JBS).23 JBS was included for its 74 
reported ability to inhibit biofilm formation in vitro and to reduce clinical symptoms after local 75 
nasal application for treatment of chronic rhinosinusitis, a biofilm infection.24 Its individual 76 
ingredients, specifically the surfactants,25 dyes,25,26, 27 and preservatives28 were also 77 
investigated to determine the antibiofilm activity of its components.  78 
To date these agents have been studied individually in different in vitro biofilm and 79 
species models, and in combination with different antimicrobial agents. However, they have 80 
not been compared against each other in a consistent model. In order to do this, we tested 81 
them in a systematic manner with the aim of identifying an ‘antibiotic enhancer’ that could be 82 
used as adjunct to antibiotics to eradicate local biofilm infections.  83 
 84 
Methods 85 
The antibiotic enhancers were tested against two biofilm - forming bacteria, 86 
Staphylococcus aureus and Pseudomonas aeruginosa, grown as biofilms on silicone discs. 87 
The agents were paired with rifampicin and clindamycin against S. aureus, and gentamicin 88 
and ciprofloxacin against P. aeruginosa. These antibiotics were chosen based on the 89 
isolates’ susceptibilities, routine clinical use, and their known anti-biofilm activity.29,30  90 
 91 
Biofilm Model 92 
 The two strains of S. aureus and P. aeruginosa strains were isolated from 93 
clinical biofilm infections (from the middle ear effusion of patients undergoing surgery for 94 
treatment of OME). Biofilms were grown on autoclaved silicone disks (6.0mm x 1.0mm, 95 
silicone elastomer MQ/VNQ/PMQ/PVMQ, Goodfellow Ltd, Cambridge, UK) in 20mL volumes 96 
of tryptone soya broth (TSB, Oxoid, Basingstoke, UK). Disks were added to a 0.5 McFarland 97 
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bacterial TSB suspension, spectrophotometer - verified to between 0.080 and 0.130 98 
absorbance at 490 nm. The 0.5 McFarland suspension containing the disks at the beginning 99 
of each “treatment” run (“treatment” in this context refers to exposure in vitro to antibiotics 100 
and/or potential enhancers) was quantified by viable counting to ensure consistency. The 101 
uninoculated control disk was added to an equal volume of TSB alone. Both groups were 102 
incubated for one hour with shaking (200 rpm) then one hour statically at 37°C for 103 
attachment to take place.  104 
After incubation, each disk was added to 1.0mL of TSB in a sterile bijou bottle and 105 
incubated for five days at 37°C without replenishing the medium, to achieve biofilm 106 
maturation. This process was repeated at the beginning of each treatment run. The model 107 
has been validated previously.31,32 108 
 109 
Sensitivity of S. aureus to rifampicin (Rifadin infusion, Sanofi – Aventis, New Jersey 110 
USA) and clindamycin (clindamycin hydrochloride, Fluka Analytical, Buchs, Switzerland) and 111 
of P. aeruginosa to gentamicin (gentamicin sulphate, Sigma-Aldrich, St Louis, MO, USA) and 112 
ciprofloxacin (ciprofloxacin hydrochloride, PanReac AppliChem, St. Louis MO, USA) was 113 
carried out in accordance with EUCAST guidelines33 and verified before each treatment by 114 
Etest (bioMérieux, Craponne, France). 115 
 116 
Potential antibiotic enhancers 117 
The concentrations of the antibiotic enhancers were determined by the literature 118 
review, using achievable, non-toxic plasma levels as a marker of safe levels (irrespective of 119 
the intended local application) of those that can be administered systemically10,18-20,22,28-30 as 120 
a guide. The following putative antibiotic enhancers were tested in the biofilm model: NAC 121 
(neutralised with sodium hydroxide), acetylsalicylic acid, sodium salicylate, salicylic acid (all 122 
Sigma-Aldrich), recombinant human deoxyribonuclease I (rhDNAse I) (Dornase alpha, 123 
Genentech, California, USA), Dispersin B (Kane Biotech, Winnipeg, Manitoba, Canada), 124 
hydrogen peroxide (Scientific Laboratory Supplies, Nottingham UK), and Johnson’s Baby 125 
Shampoo (JBS, formulation sold in England, Johnson & Johnson, New Brunswick NJ). NAC 126 
was neutralised because it is neutralised for clinical use in solutions given orally and for 127 
injection. Two different concentrations of each enhancer were examined in the experiments, 128 
with the chosen high and low concentrations added to the biofilm model shown in Table 1.  129 
 130 
Table 1: High and low concentrations of the potential antibiotic enhancers used to treat mature biofilm 131 
models 132 
Antibiotic Enhancer Treatments High concentration Low concentration 
Neutralised N-acetylcysteine 100 mg/mL 25 mg/mL 
Acetylsalicylic acid 200 µg/mL 20 µg/mL 
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Sodium salicylate 175 µg/mL 17.5 µg/mL 
Salicylic acid 150 µg/mL  15 µg/mL 
rhDNase I 100 µg/mL 10 µg/mL 
Hydrogen peroxide 30 mL/L (3%) 3 mL/L (0.3%) 
Dispersin B 20 µg/mL 2 µg/mL 
Baby Shampoo 10% 1% 
 133 
Baby Shampoo Ingredients 134 
Surfactants, preservatives and dyes in JBS were investigated for their antibiofilm 135 
activity. The surfactants investigated were sodium lauryl ether sulphate (SLES) (Mistral R&D 136 
laboratories, Antrim, Northern Ireland), sodium lauroamphoacetate (SLAA) (Colonial 137 
Chemical Inc., Pittsburg, Tennessee USA), polysorbate 20 (Sigma-Aldrich), polyethylene 138 
glycol 80 (PEG-80) (Tween 28-LQ-(CQ), Croda International Plc, Snaith, England), and 139 
polyethylene glycol distearate (PEG-150) (Evonik Industries, Essen, Germany). The 140 
preservatives were sodium benzoate and citric acid and the dyes were quinolone yellow (all 141 
Sigma-Aldrich) and Sunset Yellow FCF (Aldrich).  142 
Preliminary screening for antibacterial activity was determined by broth microdilution 143 
based on EUCAST guidance.33 Briefly, the JBS ingredient and JBS stock solutions were 144 
sterilised by autoclaving or membrane filtration. Bacteria were grown overnight on blood 145 
agar and a 0.5 McFarland suspension (spectrophotometrically adjusted) in PBS was 146 
prepared post-incubation. In triplicate, 100 μL of cation-adjusted Mueller-Hinton broth (MHB, 147 
Sigma-Aldrich) was added to each well in the 12 rows on a 96-well plate (Nunclon Delta 148 
Surface, Thermo Scientific, Roskilde, Denmark). To the first wells 100 μL of the drug 149 
standard was added, mixed, and 100 μL was transferred to the next well. The final well 150 
contained only MHB. To all wells including the MHB-only well 10 μL of the bacterial 151 
suspension was added. The plates were incubated overnight at 37°C. 152 
For preliminarily screening for the possible antibiotic - enhancing activity of the 153 
ingredients, JBS, the individual ingredients and antibiotics were tested in combination in a 154 
modified chequerboard assay.34 A 1:100 dilution of a 0.5 McFarland bacterial suspension in 155 
PBS was determined to be equivalent to 5 x105 cfu/mL for both bacteria. According to the 156 
MICs determined in the broth microdilution assay, a 4xMIC stock solution of each JBS 157 
ingredient was prepared and sterilised accordingly. A stock solution (8xMIC) of each 158 
antibiotic was prepared.  To a 96 well plate, 100 μL of MHB was added to each well. The 159 
JBS ingredient was serially diluted along the y-axis with a starting concentration of 2xMIC. 160 
The two antibiotics were serially diluted along the x-axis, with 50μL of each antibiotic stock 161 
solution added to the initial wells also to give a starting concentration of 2xMIC. All wells 162 
were inoculated with 10μL of the bacterial suspension. JBS ingredients showing potential 163 
antibacterial activity and/or interaction with the antibiotics were tested in the biofilm model at 164 
high (10xMIC) and low (1xMIC) concentrations.  165 
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 166 
Treatment of mature biofilm 167 
After five-day incubation of the silicone disks, the TSB was removed and replaced 168 
with 1.0mL of fresh TSB plus any treatment. The treatment groups were: no-treatment, 10X 169 
MIC alone, 100X MIC alone, low concentration potential antibiotic enhancer alone and 170 
paired with 10X and 100X MIC, and high concentration potential antibiotic enhancer (Table 171 
1) alone and paired with 10X MIC and 100X MIC. Experiments were performed in triplicate 172 
with an additional set of three prepared for resuscitation experiments if necessary. Where 173 
biofilms had apparently been eradicated, a further period of antibiotic-free incubation was 174 
applied to detect any sublethal suppression. Treatment was for either seven and or 14 days. 175 
Dispersin B was tested only against S. aureus, as its enzymatic activity is directed against n-176 
acetyl glucosamine and not the P. aeruginosa exopolysaccharide matrix.   177 
 178 
At the end of treatment, any surviving bacteria were quantified. Disks were removed 179 
and placed into sterile 1.5mL microtubes (Sarstedt, Nümbrecht, Germany) with 400µL of 180 
10% trypsin (gamma-irradiated, SAFC Biosciences, Hampshire, UK), which disaggregated 181 
bacteria attached to the disk. Microtubes were incubated for 15 minutes at 37°C, trypsin was 182 
replaced with 1.0mL of PBS, and all tubes were sonicated (30 kHz) for five minutes to 183 
detach bacteria from the disk. Previous work showed that trypsinisation and sonication 184 
together yielded more bacteria than each separately without loss of viability.32 The sonicate 185 
was serially diluted and 200µL of the dilutions were each spread on three blood agar plates 186 
(Oxoid), and incubated for 48 hours at 37°C 187 
 188 
Resuscitation experiments 189 
Plates were checked for growth after 24 hours. If two or more of the three plates 190 
were culture negative after 48hours, resuscitation experiments were undertaken to 191 
determine if the treatment had killed the bacteria (resuscitation negative, indicating biofilm 192 
eradication) or merely inhibited growth (resuscitation positive, indicating biofilm 193 
suppression). Disks were washed in 1.0mL PBS and placed into 1.0mL of fresh TSB to 194 
provide optimum growth conditions for six days to revive any bacteria with suppressed 195 
growth. The attached bacteria were quantified as described previously. 196 
 197 
Determining development of resistance after treatment  198 
Colonies that grew after 14 - day treatment, or were culture - negative after 14 - day 199 
treatment but then resuscitation - positive, had their MICs determined again by Etest. If small 200 
colony variants (SCVs)35 were present alongside typical colonies, each population had their 201 
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MIC determined separately. Isolates from biofilms that were not eradicated after 14 days 202 
were also investigated for resistance using EUCAST breakpoints. 203 
 204 
Scanning Electron Microscopy (SEM) 205 
 Five–day-old biofilms on silicone discs were fixed in 1.0mL of cold acetone, then 206 
dried with tetramethylsilane (Sigma-Aldrich), sputter coated with gold for 300 seconds and 207 
visualized using Jeol 6060LV variable pressure SEM (Jeol UK Ltd).  208 
 209 
Statistics 210 
 The effect of antibiotics and antibiotic enhancers between groups was compared 211 
using two-way ANOVA (Graphpad Prism 7.01, La Jolla California USA). Two-way ANOVA 212 
was conducted on the effect of the concentration of antibiotics and the antibiotic enhancer 213 
on reduction of biofilm bacteria (cfu/mL). Post-hoc multiple comparisons were only carried 214 
out when the ANOVA value was significant (p<0.05) and was corrected using Dunnett’s test. 215 
 216 
Results 217 
Susceptibility to the chosen antibiotics  218 
S. aureus was susceptible to rifampicin (MIC 0.004mg/L) and clindamycin (MIC 219 
0.064mg/L), and P. aeruginosa was susceptible to gentamicin (MIC 1.0mg/L) and 220 
ciprofloxacin (MIC 0.125mg/L). These MIC values were then used to determine the 221 
concentrations of 10xMIC and 100xMIC used with or without antibiotic enhancers to treat the 222 
biofilm model.  223 
 224 
Confirmation of biofilm growth in model 225 
S. aureus and P. aeruginosa appeared structurally as biofilms on SEM. In Figure 1b, 226 
the bacteria are more difficult to distinguish as so much polysaccharide extracellular matrix 227 
was produced that the bacteria were incompletely exposed. The discs were confirmed to be 228 
colonised with approximately 108 cfu/mL after sonication. 229 
  
 
a b 
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 230 
  
Fig 1. a. Coccus-shaped bacteria present on a silicone disc 5 days post inoculation with S. aureus. b. 231 
Rod-shaped bacteria (white arrow and elsewhere) and some encased by a matrix (black arrow) on a 232 
silicone disc, five-days post inoculation with P. aeruginosa.  Both at X2200 magnification SEM. 233 
 234 
S. aureus and P. aeruginosa both behaved functionally as biofilms in that neither was 235 
eradicated with 14 days of treatment with 10x MIC or 100x MIC antibiotics alone, although 236 
antibiotics reduced the number of viable bacteria present.  237 
 238 
Treatment of mature biofilms with antibiotics alone or in combination with potential 239 
antibiotic enhancers 240 
 Mature biofilms of S. aureus or P. aeruginosa were treated with paired antibiotics, 241 
with a potential antibiotic enhancer, or with antibiotics and the enhancers together. The 242 
results of 14 day treatments of the two biofilms are shown in Fig 2. For S. aureus, the main 243 
effect of antibiotic concentration (including no antibiotics) was statistically significant at 244 
p<0.0001 and the main effect of different antibiotic enhancers was statistically significant at 245 
p<0.0001(Fig 2A). Likewise, the main effect of antibiotic concentration was significant 246 
(p=0.0005) for P. aeruginosa and main effect of different antibiotic enhancers was significant 247 
at p<0.0001 (Fig 2B). 248 
 249 
 250 
 251 
 252 
 253 
 254 
 255 
 256 
 257 
 258 
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Fig 2: Log mean colony - forming units per millilitre (Log cfu/mL) and standard deviations for 5 - day 261 
old P. aeruginosa (A) and S. aureus (B) biofilms treated for 14 days with antibiotic enhancer and/or 262 
antibiotics (10x or 100xMIC antibiotics). The antibiotics against P. aeruginosa were ciprofloxacin and 263 
gentamicin and rifampicin and clindamycin for S. aureus. * indicates ‘inhibited’ in that treatment 264 
resulted in bacterial counts of zero but resuscitation experiments were positive for bacterial growth, 265 
whereas + indicates “eradicated” meaning that treatment resulted in bacterial counts of zero and 266 
remained negative for growth after resuscitation experiments. 267 
 268 
Biofilm eradication and inhibition were considered as the most stringent measures of 269 
efficacy rather than bacterial count reduction. JBS was the only potential antibiotic enhancer 270 
capable of eradicating both S. aureus and P. aeruginosa biofilms. 10% JBS in combination 271 
with 10xMIC antibiotics and 100xMIC antibiotics eradicated S. aureus biofilms in 14 days. 272 
JBS appeared to enhance the activity of antibiotics against the mature staphylococcal biofilm 273 
as 10xMIC and 100xMIC antibiotics without JBS were insufficient to eradicate or inhibit 274 
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biofilm. 10% JBS in combination with 100xMIC antibiotics eradicated the pseudomonas 275 
biofilm and was the only treatment to do so.  276 
 Hydrogen peroxide (3%) alone and paired with antibiotics was capable of eradicating 277 
the S. aureus biofilm after 14 days of treatment. Hydrogen peroxide with 10xMIC and 278 
100xMIC inhibited the P. aeruginosa biofilm after 14 days but did not eradicate it. 279 
 rhDNAse I (100 μg/mL) alone significantly (p<0.0001) reduced staphylococcal biofilm 280 
bacteria, but did not enhance the activity of the antibiotics. rhDNase I in combination with the 281 
100xMIC inhibited P. aeruginosa biofilm after 14 days of treatment but did not eradicate it.  282 
  283 
Development of resistance 284 
The majority of biofilms were not eradicated by 100xMIC concentrations of 285 
antibiotics. As sub-MBEC levels can result in resistance in the surviving isolates, MICs of 286 
those that survived treatment from each of the assays, including SCV populations, were 287 
determined.  288 
Resistance to rifampicin developed in seven (6.1%) of the 114 S. aureus 14 - day 289 
surviving or 14 - day resuscitated isolates tested. Of these seven, two were categorized as 290 
SCVs and six were isolates that had been resuscitated. None developed resistance to 291 
clindamycin. Of the 126 P. aeruginosa survivors four (3.2%) developed resistance to 292 
gentamicin and one developed resistance to ciprofloxacin. The five resistant P. aeruginosa 293 
survivors had all been treated with 10xMIC and rhDNase I, and four were SCVs. Of these, 294 
three were resistant to gentamicin and one to ciprofloxacin. None was resistant to both 295 
antibiotics.  296 
 297 
Screening of ingredients in baby shampoo for antibacterial activity 298 
 299 
Table 2: MIC of ingredients in baby shampoo against S. aureus and P. aeruginosa 300 
Ingredient MIC against S. aureus MIC against P. aeruginosa 
Quinolone Yellow 100 mg/mL > 100 mg/L 
Sunset Yellow 100 mg/mL > 100 mg/L 
Citric acid > 100 mg/L > 100 mg/L 
Sodium benzoate > 100 mg/L > 100 mg/L 
PEG-80 > 100 mg/L > 100 mg/L 
PEG-150 > 100 mg/L > 100 mg/L 
Polysorbate 20 > 100 mg/L > 100 mg/L 
Sodium lauroamphoacetate 22.5 mg/mL 45 mg/mL 
Sodium lauryl ether sulphate 4.2 mg/mL 4.2 mg/mL 
 301 
 302 
These results suggest that JBS may be the most promising antibiofilm agent and potential 303 
antibiotic enhancer determined by this systematic comparison. However, JBS is a complex 304 
mixture of ingredients (Table 2). To determine the active antibiofilm component of JBS, its 305 
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ingredients were screened for antibacterial activity and interaction with antibiotics and those 306 
of interest were tested in the biofilm model. 307 
The MIC of several of the ingredients was greater than any concentrations tested. Therefore, 308 
these ingredients were not tested for interaction in the checkerboard assay as they did not 309 
demonstrate an antibacterial effect at a concentration within the range of concentrations 310 
used in commercially available topical antiseptic solutions.  311 
 312 
Checkerboard assay to determine interaction of JBS ingredients with antibiotics 313 
Initially the pairs of antibiotics were screened for their drug interaction, defined as the 314 
fractional inhibitory concentration index (FICI) where FICI<0.5 indicates synergy, FICI>4.0 315 
indicated antagonism and values in between suggest no interaction.36 The FICI between 316 
gentamicin and ciprofloxacin against P. aeruginosa was 0.0625 indicating synergy (Table 3).  317 
 318 
Table 3: Drug interactions of baby shampoo and its selected ingredients in a modified chequerboard 319 
assay. ∑FICI: fractional inhibitory concentration index 320 
Ingredient in combination 
with antibiotics 
P. aeruginosa S. aureus 
FICI Drug 
Interaction 
FICI Drug 
Interaction 
Baby Shampoo 0.53 No interaction 0.375 Synergy 
Quinolone Yellow   8.0 Antagonism 
Sunset Yellow   6.0 Antagonism 
Sodium lauroamphoacetate 0.53 No interaction 0.281 Synergy 
Sodium lauryl ether sulphate 1.125 No interaction 1.125 No interaction 
 321 
Biofilm Model  322 
 SLAA and SLES were tested in the biofilm model (Fig 3). Quinolone yellow and 323 
sunset yellow were excluded as they were antagonistic when paired with antibiotics in the 324 
checkerboard assay against S. aureus. JBS was run alongside SLAA and SLES for 325 
consistency with the original experiment, and with 100xMIC antibiotics was able to eradicate 326 
mature P. aeruginosa and S. aureus biofilms after 14 days. SLAA paired with 10xMIC 327 
antibiotics was able to eradicate P. aeruginosa and S. aureus biofilms demonstrating an 328 
enhancing effect since 10xMIC alone was not capable of eradicating either biofilm.  329 
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Fig 3: Log mean colony - forming units per millilitre (Log cfu/mL) and standard deviations for five - day 332 
old P. aeruginosa (A) and S. aureus (B) biofilms treated for 14 days with JBS ingredients and/or 333 
antibiotics (10x or 100xMIC antibiotics). The antibiotics against P. aeruginosa were ciprofloxacin and 334 
gentamicin and rifampicin and clindamycin for S. aureus. * indicates ‘inhibited’ in that treatment 335 
resulted in bacterial counts of zero but resuscitation experiments were positive for bacterial growth, 336 
whereas + indicates “eradicated” meaning that treatment resulted in bacterial counts of zero and 337 
remained negative for growth after resuscitation experiments. JBS: Baby shampoo, SLES: sodium 338 
lauryl ether sulfate, SLAA: sodium lauroamphoacetate 339 
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 340 
Discussion 341 
 342 
 In this study, several literature-cited potential antibiotic enhancers were 343 
systematically evaluated against S. aureus and P. aeruginosa mature biofilm models. When 344 
used alone hydrogen peroxide and rhDNase 1 demonstrated a significant anti-biofilm effect 345 
against S. aureus (p<0.001 and p<0.001 respectively) when compared to the untreated 346 
control. Therefore, it was not possible to demonstrate potentiation of antibiotic activity for 347 
these two agents. However, 10% JBS acted as an antibiotic enhancer in combination with 348 
10xMIC, eradicating both S. aureus and P. aeruginosa biofilms with no recovery where both 349 
10xMIC and 100xMIC antibiotics alone failed to eradicate these biofilms. When the individual 350 
ingredients of the successful JBS were investigated, SLAA showed the greatest antibiofilm 351 
activity as it was able to eradicate S. aureus and P. aeruginosa biofilm in 14 days with 352 
10xMIC and 100xMIC antibiotics.  353 
  354 
The Biofilm Model 355 
The in vitro biofilm model, validated in previous studies,32 and was chosen for its 356 
ability to provide individual experimental conditions for each biofilm grown on a silicone disk. 357 
A five-day-old biofilm was considered mature and well-established based on our previous 358 
studies which demonstrated that one-day-old biofilms were easier to eradicate than five-day-359 
old ones (data not shown), consistent with the findings of Anwar et al, who showed that 360 
mature S. aureus biofilms are more difficult to treat with antibiotics than younger biofilms. 37 361 
Two antibiotics were used together according to the dual drug principle, which states that 362 
using two antibiotics of two different classes at concentrations above their MIC reduces the 363 
risk of the development of resistance.38 364 
 365 
rhDNase I 366 
rhDNAse cleaves bacterial extracellular DNA (eDNA), a component of the biofilm 367 
matrix 19. However, it did not reduce pseudomonas biofilm when used alone. The role of 368 
eDNA varies between organisms. It is required only for initial biofilm formation of P. 369 
aeruginosa 39 but it plays a more important structural role in established S. aureus biofilms 370 
compared to S. epidermidis biofilms.21  When Whitchurch et al treated a five-day-old 371 
pseudomonas biofilm with DNAse I it disrupted the biofilm, but not a seven-day old biofilm.39 372 
Our results differ from the Whitchurch et al study only in that our five-day old biofilm was not 373 
affected by rhDNase I alone, possibly due to strain differences as we used a clinically 374 
isolated strain and they used P. aeruginosa PA01, a common research strain.  375 
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Izano et al demonstrated that the exopolysaccharide matrix and eDNA have different 376 
structural roles in S. aureus and S. epidermidis biofilms, where eDNA had a more major role 377 
in the S. aureus biofilm structure. This was shown by action of rhDNAse I which inhibited 378 
biofilm formation and detached pre-formed S. aureus biofilms but not S. epidermidis biofilms. 379 
Our results are consistent with Izano et al as 100 µg/mL rhDNase I reduced biofilm in our 380 
pre-formed S. aureus biofilm model.21 381 
 382 
Hydrogen Peroxide 383 
Hydrogen peroxide eradicated staphylococcal biofilm at seven days (data not 384 
shown), alone and in combination with 100xMIC antibiotics. However, it inhibited 385 
pseudomonas biofilms only when paired with 100xMIC antibiotics. Sumen et al found that 386 
hydrogen peroxide had an ‘inhibitory effect’ on 37 biofilm organisms that they tested, and 387 
they demonstrated that its effectiveness against a broad spectrum of microorganisms unlike 388 
Dispersin B and other enzymes.22 Toté et al found that hydrogen peroxide was active 389 
against P. aeruginosa and S. aureus biofilm bacteria as well as the biofilm matrix.40 S. 390 
aureus and P. aeruginosa are catalase - positive organisms. Eradication of the biofilm may 391 
be a mechanical action in which bubbling physically disrupts the structure, or a chemical 392 
action in which the molecule itself reacts with a component of the biofilm.  393 
 394 
Baby Shampoo 395 
 JBS has been proposed as an adjuvant treatment in chronic rhinosinusitis,23 a 396 
biofilm infection, as it contains three surfactants which have also been shown to disrupt 397 
biofilms in orthopaedic infections.41 JBS is well - tolerated by users and is non-irritant. Chiu 398 
et al found that 10% JBS alone was not capable of eradicating an established pseudomonas 399 
biofilm,23 which concurs with our results. However, JBS with 100xMIC antibiotics did 400 
eradicate pseudomonas biofilm in our study and was the only treatment to do so.  401 
Furthermore, JBS with 10xMIC antibiotics also eradicated the staphylococcal biofilm, and 402 
was in fact the only treatment able to eradicate biofilm with antibiotic levels as low as this. 403 
Antibiotics alone at 10xMIC did not eradicate an established biofilm. It therefore appears that 404 
JBS enhanced the activity of the antibiotics. An antibiotic level of 10xMIC is readily 405 
achievable by local administration without toxicity, making JBS the most promising agent 406 
tested in these experiments. 407 
 From the results, it is clear that SLAA is most likely responsible. Alone, it recreates 408 
the same antibiotic - enhancing effect demonstrated by JBS. SLAA is an amphoteric 409 
surfactant, with limited data demonstrating some anti-bacterial activity,42,43 however, to our 410 
knowledge this is the first study to show the anti-biofilm activity of SLAA. Amphoteric 411 
compounds, being both anionic and cationic, have an advantage in that they have both the 412 
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detergent activity seen with anionic compounds and the bactericidal activity seen with 413 
cationic compounds.44 In the case of biofilm bacteria, it is possible that the detergent activity 414 
physically disrupts the biofilm and the bactericidal activity of SLAA and the antibiotics 415 
together can then be effective against newly-planktonic cells.   416 
 417 
Conclusions and Implications for Practice 418 
Based on the results, JBS (in particular, the SLAA component), rhDNase I and 419 
hydrogen peroxide might have a role in local therapy for local biofilm conditions such as 420 
OME, osteomyelitis, or infection of accessible implantable devices. In any situation where a 421 
local infection may be treated with antibiotic beads or in which the infected area may be 422 
irrigated with an antibiotic solution, the enhancer could be added alongside. Irrigation of 423 
infected wounds is common practice and antibiotics or antiseptics may be added to the 424 
irrigation fluid.45 Considering the high acceptability of JBS in both medical use and for its 425 
original, intended hair shampoo use, that rhDNase I is approved for use in the lungs by 426 
inhalation,46 and that hydrogen peroxide has many historical antiseptic uses, these three 427 
agents are likely to have satisfactory safety profiles. Furthermore, success in this 428 
experimental setting was considered to be complete eradication of biofilm, but in vivo a 429 
significant reduction in bacterial counts might be considered a success in certain 430 
circumstances. It is accepted that results of in vitro evaluations do not always apply in vivo, 431 
nevertheless we feel that on safety and in vitro grounds the enhancers show clinical 432 
promise. Future in vivo studies are planned to look at JBS or its active component, SLAA, as 433 
an adjunct to local antibiotic treatment for infections such as otitis externa, OME, and 434 
infected wounds.  435 
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